Skip to content

Effect of tranexamic acid on blood protection in patients undergoing total hip arthroplasty

Effect of tranexamic acid on blood protection in patients undergoing total hip arthroplasty

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045474
Enrollment
Unknown
Registered
2021-04-16
Start date
2021-04-19
Completion date
Unknown
Last updated
2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blood protection

Interventions

Group A:tranexamic acid low-dose group, 0.5g tranexamic acid intravenous drip before skin incision + 0.5g tranexamic acid intravenous drip after prosthesis installation
Group B: tranexamic acid high-dose group, 1 g tranexamic acid intravenous drip before skin incision + 1 g tranexamic acid intravenous drip after prosthesis installation
group C:control group, 100 ml normal saline intravenous drip before skin incision + 100 ml normal saline intravenous drip after prosthesis installation
group D:tranexamic acid pump group, 1 g tranexamic acid intravenous drip before skin incision + 0.5 g / h tranexamic acid continuous pump for 2 hours

Sponsors

The First People's Hospital of Nanning
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years, ASA classification II~IV; 2. Patients who intend to undergo total hip replacement surgery under intraspinal anesthesia; 3. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Re-operation of the hip joint; 2. Those who are allergic to tranexamic acid ingredients; 3. Patients with thrombosis.

Design outcomes

Primary

MeasureTime frame
the amount of blood loss (intraoperative blood loss + drainage volume 48 hours after operation);the amount of blood transfusion;Thromboelastogram;coagulation function;routine blood test;

Secondary

MeasureTime frame
Ultrasound examination of lower extremity vessels;renal dysfunction;thromboembolism;epilepsy;death;

Countries

China

Contacts

Public ContactDeng Jicai

The First People's Hospital of Nanning

247545782@qq.com+86 19977183773

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026